ABSTRACT
Gastric hyperplastic polyps constitute one of the most common types of polyp in patients undergoing an upper endoscopy, and are found with a frequency as high as 60% of all polyps. However, isolated diffuse hyperplastic gastric polyposis is seldom reported. Here, we present a case of isolated diffuse hyperplastic gastric polyposis in a 30-year-old man who was investigated for iron deficiency anemia during routine screening. Esophagogastroduodenoscopy revealed numerous polyps on the antrum of the stomach, and the polyps were removed completely by endoscopic polypectomy. An adenocarcinoma that arose from a large hyperplastic polyp was found after its removal. This case suggests that despite the rarity of isolated diffuse hyperplastic gastric polyposis, it can be managed by endoscopic treatment.
Subject(s)
Adult , Humans , Adenocarcinoma , Anemia, Iron-Deficiency , Endoscopy , Endoscopy, Digestive System , Mass Screening , Polyps , StomachABSTRACT
An inflammatory myofibroblastic tumor (IMT) is a rare disease entity, and the clinical characteristics range from indolent to aggressive forms. No established management for patients with unresectable or aggressive IMT is available. We report on a 62-year-old patient with aggressive IMT who achieved a durable partial response lasting 12 months after anthracycline-containing cytotoxic chemotherapy without corticosteroids. The patient was admitted for an evaluation of progressive weight loss and lower abdominal pain lasting for 2 weeks. Abdominopelvic computed tomography revealed a 10 cm sized heterogeneous mass in the mesentery that encased the superior mesenteric artery and a liver metastasis. The diagnosis of IMT was confirmed by percutaneous core needle biopsy of the mesenteric mass. Systemic chemotherapy was performed after confirming disease progression during a 1 month observation period. A partial response was obtained after two cycles of chemotherapy. Anthracycline-containing cytotoxic chemotherapy could be a treatment option for patients with aggressive IMT.
Subject(s)
Humans , Middle Aged , Abdominal Pain , Adrenal Cortex Hormones , Benzeneacetamides , Biopsy, Large-Core Needle , Disease Progression , Liver , Mesenteric Artery, Superior , Mesentery , Myofibroblasts , Neoplasm Metastasis , Piperidones , Rare Diseases , Weight LossABSTRACT
A desmoplastic small-round-cell tumor (DSRCT) is a rare, aggressive neoplasm that develops mostly in the abdominal cavity in children and young adults. We present a case of a 19-year-old male with right upper quadrant discomfort for 3 months. On abdominal computerized tomography, multiple huge and demarcated masses were found in the liver, retroperitoneal lymph nodes, and peritoneal and retroperitoneal cavities. Fine needle aspiration biopsy of the hepatic mass was performed and DSRCT was diagnosed by hematoxylin and eosin staining and immunohistochemical analysis. He was treated initially with high-dose systemic chemotherapy (alternating schedules of cyclophosphamide, vincristine, doxorubicin, ifosfamide, and etoposide), underwent two debulking surgeries and pelvic irradiation between systemic chemotherapy schedules, and achieved complete remission after the 15 months of treatment duration. We report this case to emphasize the importance of aggressive local treatment modalities as well as high-dose systemic chemotherapy for treatment of DSRCT even with initially unresectable or extensively metastatic presentation.
Subject(s)
Child , Humans , Male , Young Adult , Abdominal Cavity , Appointments and Schedules , Biopsy , Biopsy, Fine-Needle , Cyclophosphamide , Desmoplastic Small Round Cell Tumor , Doxorubicin , Eosine Yellowish-(YS) , Hematoxylin , Ifosfamide , Liver , Lymph Nodes , VincristineABSTRACT
An inflammatory myofibroblastic tumor (IMT) is a rare disease entity, and the clinical characteristics range from indolent to aggressive forms. No established management for patients with unresectable or aggressive IMT is available. We report on a 62-year-old patient with aggressive IMT who achieved a durable partial response lasting 12 months after anthracycline-containing cytotoxic chemotherapy without corticosteroids. The patient was admitted for an evaluation of progressive weight loss and lower abdominal pain lasting for 2 weeks. Abdominopelvic computed tomography revealed a 10 cm sized heterogeneous mass in the mesentery that encased the superior mesenteric artery and a liver metastasis. The diagnosis of IMT was confirmed by percutaneous core needle biopsy of the mesenteric mass. Systemic chemotherapy was performed after confirming disease progression during a 1 month observation period. A partial response was obtained after two cycles of chemotherapy. Anthracycline-containing cytotoxic chemotherapy could be a treatment option for patients with aggressive IMT.
Subject(s)
Humans , Middle Aged , Abdominal Pain , Adrenal Cortex Hormones , Benzeneacetamides , Biopsy, Large-Core Needle , Disease Progression , Liver , Mesenteric Artery, Superior , Mesentery , Myofibroblasts , Neoplasm Metastasis , Piperidones , Rare Diseases , Weight LossABSTRACT
Carbon monoxide is a nonirritant, odorless, colorless gas. Its effects are prominent in organs most sensitive to oxygen deprivation, such as the heart, brain, and kidney. Although less frequently, an association between thromboembolic events and carbon monoxide poisoning has been shown in the literatures. In this case, we report a case of atrial thrombus associated with carbon monoxide poisoning.
Subject(s)
Brain , Carbon , Carbon Monoxide , Carbon Monoxide Poisoning , Heart , Heart Atria , Kidney , Oxygen , ThrombosisABSTRACT
Adrenal insufficiency during the treatment of pulmonary tuberculosis is a troublesome condition and can at times be lifethreatening if untreated. Rifampin is one of the most widely prescribed anti-tuberculosis agents. Furthermore, rifampin has been known to be capable of affecting the metabolism of various medications, including glucocorticoids. In this paper, a case of recurrent adrenal insufficiency induced by rifampin during the treatment of pulmonary tuberculosis is reported. The patient was a 63-year-old man who was diagnosed with Addison's disease 17 years earlier and had been undergoing glucocorticoid replacement therapy. Five months before, the patient manifested pulmonary tuberculosis and was immediately given anti-tuberculosis medication that included rifampin. After one week of medication, general weakness and hyponatremia occurred. Despite the increased dose of the glucocorticoid medication, the adrenal insufficiency recurred many times. Since the substitution of levofloxacin for rifampin, the episodes of adrenal insufficiency have not recurred so far.